Capricor Therapeutics (CAPR) Competitors $13.07 +0.17 (+1.32%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CAPR vs. CPRX, AGIO, PTGX, AMRX, LBPH, LGND, GERN, NAMS, IDYA, and CNTAShould you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Catalyst Pharmaceuticals (CPRX), Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), Amneal Pharmaceuticals (AMRX), Longboard Pharmaceuticals (LBPH), Ligand Pharmaceuticals (LGND), Geron (GERN), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical preparations" industry. Capricor Therapeutics vs. Catalyst Pharmaceuticals Agios Pharmaceuticals Protagonist Therapeutics Amneal Pharmaceuticals Longboard Pharmaceuticals Ligand Pharmaceuticals Geron NewAmsterdam Pharma IDEAYA Biosciences Centessa Pharmaceuticals Catalyst Pharmaceuticals (NASDAQ:CPRX) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and community ranking. Does the media prefer CPRX or CAPR? In the previous week, Catalyst Pharmaceuticals had 4 more articles in the media than Capricor Therapeutics. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 1 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.94 beat Catalyst Pharmaceuticals' score of 1.13 indicating that Capricor Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Capricor Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is CPRX or CAPR more profitable? Catalyst Pharmaceuticals has a net margin of 31.01% compared to Capricor Therapeutics' net margin of -146.86%. Catalyst Pharmaceuticals' return on equity of 40.79% beat Capricor Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Catalyst Pharmaceuticals31.01% 40.79% 34.87% Capricor Therapeutics -146.86%-112.95%-57.00% Which has more risk & volatility, CPRX or CAPR? Catalyst Pharmaceuticals has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 3.98, suggesting that its stock price is 298% more volatile than the S&P 500. Do analysts rate CPRX or CAPR? Catalyst Pharmaceuticals presently has a consensus target price of $31.14, suggesting a potential upside of 46.42%. Capricor Therapeutics has a consensus target price of $34.50, suggesting a potential upside of 163.96%. Given Capricor Therapeutics' higher probable upside, analysts clearly believe Capricor Therapeutics is more favorable than Catalyst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Catalyst Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Capricor Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CPRX or CAPR? Catalyst Pharmaceuticals received 136 more outperform votes than Capricor Therapeutics when rated by MarketBeat users. Likewise, 74.70% of users gave Catalyst Pharmaceuticals an outperform vote while only 63.52% of users gave Capricor Therapeutics an outperform vote. CompanyUnderperformOutperformCatalyst PharmaceuticalsOutperform Votes49374.70% Underperform Votes16725.30% Capricor TherapeuticsOutperform Votes35763.52% Underperform Votes20536.48% Do institutionals & insiders believe in CPRX or CAPR? 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are owned by company insiders. Comparatively, 12.0% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation & earnings, CPRX or CAPR? Catalyst Pharmaceuticals has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCatalyst Pharmaceuticals$460.48M5.51$71.41M$1.1818.03Capricor Therapeutics$23.23M25.59-$22.29M-$1.06-12.33 SummaryCatalyst Pharmaceuticals beats Capricor Therapeutics on 12 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPR vs. The Competition Export to ExcelMetricCapricor TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$594.29M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-12.3310.5991.3417.19Price / Sales25.59195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book17.905.104.794.78Net Income-$22.29M$151.51M$120.07M$225.60M7 Day Performance-1.43%-2.15%-1.89%-1.24%1 Month Performance-27.11%-3.14%11.45%3.36%1 Year Performance192.39%11.50%30.61%16.58% Capricor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPRCapricor Therapeutics3.2062 of 5 stars$13.07+1.3%$34.50+164.0%+199.8%$594.29M$23.23M-12.33N/APositive NewsGap DownHigh Trading VolumeCPRXCatalyst Pharmaceuticals4.6353 of 5 stars$21.76+1.8%$31.14+43.1%+48.7%$2.60B$398.20M18.12167AGIOAgios Pharmaceuticals4.2921 of 5 stars$43.98+12.9%$56.33+28.1%+53.6%$2.51B$32.87M3.73390Analyst ForecastPTGXProtagonist Therapeutics3.5882 of 5 stars$41.57+1.2%$53.78+29.4%+100.0%$2.48B$60M15.44125News CoveragePositive NewsAMRXAmneal Pharmaceuticals2.8823 of 5 stars$7.73-1.3%$10.00+29.4%+47.1%$2.40B$2.68B-11.387,700Analyst DowngradeNews CoverageLBPHLongboard Pharmaceuticals0.6628 of 5 stars$59.98+0.0%$59.56-0.7%+986.6%$2.34BN/A-26.9020LGNDLigand Pharmaceuticals4.983 of 5 stars$122.83+5.1%$147.00+19.7%+65.4%$2.32B$152.42M47.4480Analyst RevisionGERNGeron3.8435 of 5 stars$3.78-2.1%$7.15+89.2%+61.6%$2.29B$29.48M-12.06141Short Interest ↓NAMSNewAmsterdam Pharma2.8064 of 5 stars$24.67-0.1%$36.20+46.7%+142.4%$2.28B$33.59M0.0057Insider TradeAnalyst RevisionGap DownIDYAIDEAYA Biosciences4.3228 of 5 stars$25.88+2.7%$53.67+107.4%-23.7%$2.24B$3.92M-10.8180Analyst ForecastCNTACentessa Pharmaceuticals2.9987 of 5 stars$16.53-0.2%$25.83+56.3%+131.0%$2.18B$6.85M-10.8372Insider Trade Related Companies and Tools Related Companies CPRX Competitors AGIO Competitors PTGX Competitors AMRX Competitors LBPH Competitors LGND Competitors GERN Competitors NAMS Competitors IDYA Competitors CNTA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CAPR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAPR Stock Alerts